Merck KGaA has reached an agreement with SpringWorks on a $47-per-share ... coming after it paid Chinese biotech Abbisko Therapeutics $70 million upfront for rights to pimicotinib, a drug in ...

DataM Intelligence | competitive Intelligence NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibito ...

Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...